Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:1/15/2014)... /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from ... China,s orthopedic instrument industry has seen ... rising from 3.28 billion yuan in 2006 to 9.85 ...
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... HILL, N.C., Jan. 13, 2012  Facing patent cliffs and ... - either through in-licensing deals or M&A activities - ... a sound strategy, but a difficult one to effectively ... consummating a business is fraught with potential pitfalls. With ...
... 2012 The Academy of Managed Care Pharmacy (AMCP) ... Audit Guidelines for Pharmacy Claims – a resource ... and addresses a challenge between the community and managed ... ) The 21-page Model ...
Cached Medicine Technology:Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2Academy of Managed Care Pharmacy (AMCP) Releases Model Audit Guidelines for Pharmacy Claims 2Academy of Managed Care Pharmacy (AMCP) Releases Model Audit Guidelines for Pharmacy Claims 3
(Date:4/22/2014)... device has been shown to reduce seizures in patients ... When coupled with an innovative electrode placement planning system ... complete elimination of seizures in nearly half of the ... , That,s good news for a large portion of ... epilepsy whose seizures can,t be controlled with medications and ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
(Date:4/22/2014)... scientists have found a way to block abnormal cholesterol ... atherosclerosis, the main cause of heart attacks and strokes ... condition develops when fat builds inside blood vessels over ... reducing their ability to feed oxygen-rich blood to the ... of experiments, described April 7 in the journal ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... N.J., March 9 Schering-Plough Corporation (NYSE: ... Barclays Capital Global Healthcare Conference in Miami, on ... be participating in various investor and employee communications ... earlier today, and therefore, will not be able ...
... Catholic Priest Co-Founded Father Martin,s Ashley Treatment Center in ... Joseph C. Martin, S.S., noted authority and lecturer on ... center in Havre de Grace, MD, died today at ... 84.Best known for his lectures on alcoholism as a ...
... Corporate Services has partnered with McNamara & Associates ... consulting services to its member hospitals for controlling ... on the heels of The Violence Prevention in ... to establish a plan to identify and combat ...
... The Providence Service Corporation (Nasdaq: PRSC ) today ... its fourth quarter and year ended December 31, 2008 on ... a conference call at 11:00 a.m. EDT (9:00 a.m. MDT ... March 16, 2009, to discuss its financial results and corporate ...
... S.C., March 9 The BlueCross BlueShield of South ... implement the Nurse-Family Partnership program in Horry County to ... presentation event will begin at noon, March 13, in ... North Oak Street, Myrtle Beach, S.C.The BlueCross Foundation is ...
... security against the disease, study finds , , MONDAY, March 9 ... gene that puts them at higher risk of breast cancer ... , Several type of risk management strategies are available to ... which is known to elevate a woman,s risk of breast ...
Cached Medicine News:Health News:The Rev. Joseph C. Martin, Leading Authority on Alcoholism and Addiction Treatment, Dies at 84 2Health News:The Rev. Joseph C. Martin, Leading Authority on Alcoholism and Addiction Treatment, Dies at 84 3Health News:The Rev. Joseph C. Martin, Leading Authority on Alcoholism and Addiction Treatment, Dies at 84 4Health News:NJHA, McNamara and Associates Inc. Team Up to Provide Strategies for Controlling Workplace Violence 2Health News:Providence Service Corporation to Report Fourth Quarter and Year End 2008 Results on Monday, March 16th Before the Market Opens 2Health News:Providence Service Corporation to Report Fourth Quarter and Year End 2008 Results on Monday, March 16th Before the Market Opens 3Health News:S.C. BlueCross Foundation to Grant More Than $1.3 Million to Support First Time Mothers in Horry County 2Health News:Women With Breast Cancer Gene Favor Preventive Mastectomy 2
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...
Refrigerator specially designed for the storage of blood in standard 500ml bags, complying with Australian Standard AS3864 1997....
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
Medicine Products: